Novum Peptides

Research use only

Before you enter

Please confirm the following before browsing Novum Peptides.

Adults onlyYou must be 18 years or older to enter.

Laboratory research onlyOur products are not for human or veterinary use.

We’ll remember your confirmation on this browser where storage is available.

Novum Peptides · For laboratory research only

Tandem mass spectrometry and peptide fragments

Understand precursor selection, b- and y-type fragment labels, sequence coverage and the limits of an annotated peptide MS/MS spectrum.

Tandem mass spectrometry examines fragments produced from selected precursor ions. A peptide's intact mass constrains its total composition; fragment information can help locate residues and modifications along the chain. Interpreting the result means connecting observed signals to a proposed sequence while checking which positions the evidence actually distinguishes.

Separate precursor selection from fragment interpretation

In a typical peptide MS/MS experiment, an isolation step selects a range of precursor m/z values, fragmentation generates product ions, and a subsequent mass analysis measures those products. The fragment spectrum adds information beyond the intact precursor mass.

The precursor label matters because it defines the molecule, charge and isotope assignment being investigated. A mistaken starting assignment can distort the interpretation of apparently plausible fragments. Fragmentation method also matters: different methods favour different product-ion series and retain or lose chemical groups differently.Matrix Science — Introduction to database searching using Mascot (opens in a new tab)

A useful report therefore connects the fragment spectrum to its selected precursor and analytical method. A detached list of fragment masses omits the context needed to judge how those signals were produced.

Read fragment direction and residue count

For common peptide backbone-fragment nomenclature, b-type ions retain the N-terminal part of the sequence and y-type ions retain the C-terminal part. The subscript indicates the number of residues represented in that fragment. Matrix Science's technical training materials explain these series and distinguish them from alternatives produced by other fragmentation methods.Matrix Science — Introduction to database searching using Mascot (opens in a new tab)

Original sequence example: Ala–Gly–Ser–Leu
LabelResidues represented
b2Ala–Gly, counted from the N terminus
b3Ala–Gly–Ser, counted from the N terminus
y2Ser–Leu, counted from the C terminus
y3Gly–Ser–Leu, counted from the C terminus

These labels specify fragment-ion families, not neutral peptides created by simply cutting and adding water. Calculating their m/z requires the appropriate fragment chemistry and charge. The table illustrates residue membership without assigning fabricated experimental masses.

At matching charge, the difference between adjacent members of one series can support a residue assignment. In the example, the change from b2 to b3 corresponds to adding the serine residue contribution. It is not the mass of a free serine molecule with its separate terminal groups.

Ask which sequence positions are actually supported

An annotated spectrum may support some stretches of a candidate sequence more strongly than others. A convincing series across a distinguishing position is more informative for that question than many assigned peaks elsewhere. Reported coverage should therefore be read alongside the positions and types of the matched fragments.

Missing expected fragments do not automatically establish that a residue is absent. Ion formation, abundance, detection and processing affect which products appear. Equally, adding a label beside a peak does not make the assignment unique when several candidate fragments could fit it.

Allow for more than one precursor contributing

Precursor isolation can capture more than one species. The primary study on chimera-spectrum diagnostics using two-dimensional partial-covariance mass spectrometry addresses co-isolation and co-fragmentation of peptides, including isobaric or isomeric cases. It demonstrates why a fragment spectrum can contain contributions that do not all belong to one proposed sequence.Chimera spectrum diagnostics for peptides using two-dimensional partial covariance mass spectrometry (opens in a new tab)

For interpretation, retain isolation information and unexplained signals rather than forcing every feature onto the preferred candidate. Consider whether overlapping precursors could account for conflicting fragments. This does not mean every mixed-looking spectrum is unusable; it means the assignment must explain the relevant evidence.

A defensible sequence conclusion states the candidate, supporting fragments, unresolved alternatives and analytical limits. It keeps fragment evidence connected to the broader identity assessment without turning a partial match into a claim that every structural detail has been established.

Sources and further detail

  1. Matrix Science — Introduction to database searching using Mascot (opens in a new tab)

    Developer technical training, including b/y series and fragmentation nomenclature. The four-residue example is original.

  2. Chimera spectrum diagnostics for peptides using two-dimensional partial covariance mass spectrometry (opens in a new tab)

    Primary 2021 study addressing co-isolated/co-fragmented peptide contributions; specialised method performance is not generalised to routine certificates.

Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.